Company* |
Company* |
Type/Product Area | Terms/Details (Date) |
| | |||
Abmaxis Inc.* |
BioArctic Neuroscience AB* (Sweden) |
Collaboration to develop a human monoclonal antibody for treating Alzheimer's disease |
Abmaxis will further optimize and humanize BioArctic's murine antibodies; Abmaxis gets an up-front license fee and could receive milestone and royalty payments (10/6) |
Abmaxis Inc.* |
MaimoniDex RA Ltd.* (Israel) |
Deal to jointly develop a human monoclonal antibody for treating rheumatoid arthritis and other inflammatory diseases |
Abmaxis will humanize and optimize the murine antibody from MaimoniDex and be entitled to up-front, milestone and royalty payments (9/21) |
Accelr8 |
Promega Corp.* |
Deal to develop Accelr8's OptiChem surface chemistry for use in microarraying slides |
They will explore new techniques in micro- array research using their respective technologies (10/17) |
Advancis |
Undisclosed private company |
Advancis agreed to sell U.S. rights to the Keflex brand of cephalexin to the company |
Advancis got $1M up front and expects to get $11M when the deal closes, plus up to $3M in milestone payments for the approved antibiotic (9/15) |
Aeres |
Lpath Therapeutics Inc.* |
Deal to humanize Lpath's sphingomab murine antibody |
The antibody has shown activity against cancers; terms of the deal were not disclosed (9/19) |
Alnylam |
Qiagen NV (the Netherlands; QGEN) |
Qiagen got nonexclusive rights to provide research products and services in RNA interference |
Alnylam's Kreutzer-Limmer patent family covers small interfering RNAs and their use to mediate RNAi in mammalian cells; terms of the deal were not disclosed (9/21) |
Amgen Inc. |
ViaCell Inc. (VIAC) |
ViaCell licensed rights to use recombinant human granulo-cytecolony stimulating factor, expanding an earlier deal |
License covers development of a cellular therapy product to treat hematological malignancies and genetic diseases; Amgen got a warrant to purchase 200,000 ViaCell shares; further terms were not disclosed (8/30) |
Aradigm |
United Therapeutics Corp. (UTHR) |
Deal to develop an inhaled, liposomal formulation of treprostinil, a drug approved for treating pulmonary arterial hypertension |
The goal is to deliver the prostacyclin analogue named Remodulin in Aradigm's AERx System; Aradigm is entitled to development fees, milestone payments and royalties on any resulting sales (10/24) |
Argenta |
Cellzome Inc.* |
Companies entered a drug discovery collaboration |
Argenta will apply its medicinal chemistry, assay development and screening capabilities in the deal, terms of which were not disclosed (8/29) |
Array |
Genentech Inc. (NYSE:DNA) |
They extended for a second time a January 2004 deal to discover small-molecule drugs for treating cancer |
Array could get up to $50M in research funding over three years; Array also is entitled to milestone and royalty payments (10/13) |
Avantogen |
Hawaii Biotech Inc.* |
Nonexclusive deal under which HawaiiBio will evaluate Avantogen's GPI-0100 adjuvant |
HawaiiBio plans to develop vaccines for infectious diseases; Avantogen is entitled to sublicense fees, milestone payments and royalties on resulting sales (10/12) |
Avidia Inc.* |
MedImmune Inc. (MEDI) |
Collaboration to develop anti- cancer products targeting the receptor tyrosine kinase cMET |
They will develop two other targets using Avidia's Avimer technology; Avidia is entitled to an up-front fee, milestone payments and royalties on any resulting sales (10/20) |
Axordia Ltd.* |
Serologicals Corp. (SERO) |
Exclusive deal to co-develop antibody markers from Axordia's human embryonic stem cell lines |
Serologicals subsidiary Chemicon International Inc. would commercialize any resulting antibody research tools; terms were not disclosed (9/30) |
Cellectis SA* |
Biogen Idec Inc. (BIIB) |
Cellectis will develop a custom meganuclease recombination system for Biogen |
The system will be designed to enable reproducible high-yield production of target proteins in mammalian cells; terms were not disclosed (9/21) |
Crucell NV |
IQ Corp.* (the Netherlands) |
IQ got a license to use the PER.C6 cell line for producing monoclonal antibodies |
Crucell and DSM are entitled to a signing fee and annual maintenance fees; further terms were not disclosed (10/19) |
CombinatoRx |
Angiotech Pharmaceuticals Inc.(Canada; ANPI) |
Deal to develop drug devices and therapeutics built from CombinatoRx's expertise in drug combinations; Angiotech has an option to get exclusive licenses in certain applications |
CombinatoRx gets an up-front license fee of $27M plus a $15M equity investment; Angiotech may license up to 10 compounds under the deal and may license up to five more for $2M each; CombinatoRx could get mile- stones of up to $30M per compound and royalties on any resulting sales (10/3) |
Curis Inc. |
Genentech Inc. (NYSE:DNA) |
Genentech extended funding of their deal to develop cancer drugs through June 2006 |
Curis gets another $1.25M to support personnel working on Hedgehog antagonist technologies (10/13) |
Cyclacel Group |
Genzyme Corp. (GENZ) |
Genzyme got an option to license two preclinical CDK inhibitors for treating renal diseases and certain related conditions |
The deal on the cyclin-dependent kinase inhibitors does not include rights in oncology or other areas; Genzyme will evaluate the compounds under undisclosed terms (9/14) |
DiNonA Inc.* |
EvoGenix Ltd. (Australia; ASX:EGX) |
EvoGenix licensed worldwide rights to an antibody for treating leukemia |
Terms of the deal were not disclosed (9/19) |
Eidogen- |
KAI Pharmaceuticals* |
Services deal under which Eidogen will characterize protein kinase C regulatory domains for KAI |
Eidogen will use technologies from its DirectDesign Discovery Service in the deal; terms were not disclosed (10/18) |
Eidogen- |
Medisyn Technologies Inc.* |
Medisyn got a license to the Kinase Knowledgebase from Eidogen |
The product is a database of structure- activity relationships and chemical synthesis data focused on protein kinases (9/7) |
Eiffel |
MAP Pharmaceuticals Inc.* |
MAP got exclusive rights to use Eiffel's technology for the pulmonary delivery of insulin and the delivery of steroids with or without beta agonists |
Eiffel gets $0.6M to fund a specific program of process development work; it also is entitled to milestone payments and royalties on any resulting sales (9/22) |
Evotec AG |
Genedata AG* (Switzerland) |
Co-marketing deal to offer high-content and high-throughput screening |
They will combine products to offer a one- stop solution for potential customers (9/13) |
ExonHit |
Affymetrix Inc. (AFFX) |
Deal to combine Affymetrix's GeneChip microarray platform and ExonHit's alternative RNA splicing technologies |
The first arrays with the ExonHit Splice- Array content are expected to be available by the end of 2005; ExonHit is entitled to license payments (10/17) |
Galapagos NV |
Serono SA (Switzerland; NYSE:SRA) |
Galapagos will supply compounds from its SoftFocus collection for use in Serono's drug discovery programs |
Also, medicinal chemistry services being provided by Galapagos division BioFocus will be expanded; Galapagos gets technology access fees and fees for chemistry services (10/18) |
Galapagos NV |
Amsterdam Molecular Therapeutics BV* (the Netherlands) |
Collaboration to develop treatments for acute spinal cord and peripheral nerve damage |
The collaboration also includes the Netherlands Institute for Brain Research and the Vrije Universiteit Amsterdam and is being supported by a grant from the Dutch government (9/14) |
GenVec Inc.(GNVC) |
Unnamed entity |
Letter of intent calls for sale of GenVec's myoblast cell therapy program for treating congestive heart failure |
GenVec would get royalties on any resulting revenues; the technology was acquired through GenVec's 2003 merger with Diacrin Inc. (10/18) |
Hyperion |
IR BioSciences Holdings Inc. (OTC BB:IRBO) |
Hyperion will perform research on IR's anthrax agent Viprovex |
Hyperion is working with IR subsidiary ImmuneRegen BioSciences in the deal; terms were not disclosed (10/20) |
Icoria Inc. |
Unnamed company |
Icoria will provide microarray expression services to the undisclosed company |
Services under the contract will be performed by Icoria's gene expression profiling unit Paradigm Array Labs (9/8) |
Illumina Inc.(ILMN) |
PharmacoDesign* (South Korea) |
PharmacoDesign acquired a BeadStation system and genotyping arrays and reagents |
PharmacoDesign will genotype various Korean populations to study certain diseases; Illumina has rights to incorporate resulting biomarkers into SNP panels under an exclusive, royalty-bearing license (10/25) |
Ingenuity |
Genizon BioSciences Inc.* |
Genizon licensed the Ingenuity Pathways Analysis 3.0 system Serologicals subsidiary |
The application will be used to identify targets; terms were not disclosed (10/25) |
Innovata plc |
Serologicals |
Celliance acquired ubiquitous chromatin opening element gene expression technology |
The technology is used in protein production; Innnovata previously said the technology was not core to its business; terms of the deal were not disclosed (10/3) |
Institute of |
Stem Cell Therapy International Inc. (OTC BB:ATYD) |
Stem Cell got global rights for the supply of stem cells and the use of 26 related patents |
Terms of the deal were not disclosed (9/19) |
Isis |
iCo Therapeutics Inc.* |
iCo got exclusive rights to develop and sell ISIS 13650, a second-generation antisense drug |
Isis gets cash and a note convertible into iCo equity up front, along with potential milestone and royalty payments; the drug initially will be developed for eye diseases (8/25) |
Key Organics |
Reaction Biology Corp.* |
They created a joint venture to engage in high-throughput drug discovery |
The plan is to identify potential drug compounds and then to partner or sell them to pharmaceutical companies (8/29) |
Medarex Inc. |
ImClone Systems Inc. (IMCL) |
ImClone licensed rights to use Medarex's UltiMAb system to develop human antibody product candidates |
Medarex will get license fees and could receive milestone and royalty payments from resulting products (9/12) |
Medicago Inc.* |
Acambis plc (UK; ACAM) |
Deal to evaluate the expression of recombinant vaccines using Medicago's plant-based Proficia system |
Medicago is entitled to milestone payments in the deal (9/27) |
Medisyn |
Humanetics Corp.* |
Collaboration to develop natural, non-prescription compounds focused on disease prevention |
Medisyn will provide natural compounds; Humanetics will be responsible for clinical development; further terms were not disclosed (10/20) |
Memory |
Amgen Inc. (AMGN) |
Collaboration to develop PDE10 inhibitors for indications including certain neurological and psychiatric disorders |
Memory gets an up-front payment of $5M and could get $5.1M in research funding over two years; it also is entitled to milestone and royalty payments (10/17) |
Mucosal |
Serenex Inc.* |
Serenex got worldwide rights to SNX-1012 for chemotherapy-and radiation-induced oral mucositis |
Phase II trials on the product are being planned; terms of the license deal were not disclosed (10/6) |
MultiCell |
Living Cell Technologies Ltd. (Australia; ASX:LCT) |
They formed a joint venture to develop therapeutic liver cell applications |
MultiCell will develop extended functionality of its adult liver stem cells and immortalized human hepatocytes using LCT's encapsulation technology; they will co-own resulting products (10/4) |
NatImmune |
Enzon Pharmaceuticals Inc. (ENZN) |
Enzon licensed recombinant human mannaninding lectin, a protein being developed to prevent severe infections topical formulations (10/3) |
NatImmune gets $10M up front and is entitled to milestone and royalty payments; NatImmune retains rights in the Nordic countries and has certain rights to develop |
OctoPlus |
SingVax Pte. Ltd.* (Singapore) |
Collaboration to co-develop a single-shot Japanese encephalitis vaccine |
SingVax will be responsible for various development activities; OctoPlus will be responsible for formulation work; they will share costs and any profits (9/26) |
OriGene |
Cytomyx Holdings plc* (UK) |
Deal to co-develop tools to pro- file gene expression and biomarker validation in a range of cancers |
Terms of the deal were not disclosed (10/17) |
Peregrine |
Medarex Inc. |
Medarex got rights to develop and sell its anti-PSMA monoclonal antibody conjugated to therapeutic agents for use in cancer therapies |
Peregrine gets an up-front payment and annual maintenance fees, as well as potential milestones and royalties for the license to its Vascular Targeting Agent technology platform (8/25) |
Prima Biomed |
Xencor Inc.* |
Xencor got a nonexclusive license to use Fc receptor technology for research and an option to use the technology in development |
Prima subsidiary Arthron Pty. Ltd. gets an up-front fee and annual license fees, and would get additional fees and be entitled to milestone payments, if Xencor exercises its development option (9/8) |
Provid |
Palatin Technologies Inc.(AMEX:PTN) |
Research services deal under which Provid will optimize leads for Palatin |
Provid will use its technologies on drug candidates identified using Palatin's MIDAS technology; terms were not disclosed (10/17) |
RenaMed |
Genzyme Corp. (GENZ) |
Deal to develop and sell RenaMed's Bio- replacement Therapy for treating acute renal failure |
Genzyme will spend $23M through 3Q:06 to support development and could pay $20M in development milestones, plus regulatory milestones; costs and any profits will be equally shared (9/28) |
RheoGene |
Xenogen Corp. |
Xenogen got rights to use the RheoSwitch System to develop transgenic mice |
They also will collaborate on projects aimed at controlling delivery and regulating expression of RNAi; terms were not disclosed (9/14) |
Rigel |
Serono SA (Switzerland; NYSE:SRA) |
Serono got exclusive rights to develop and sell products from Rigel's Aurora kinase inhibitor program; the license is worldwide except Japan |
Rigel gets a $10M license fee and a $15M equity investment at a premium up front; development and sales milestones could push the total value to $160M, plus royalties on any resulting sales (10/25) |
Rosetta |
Ambion Inc.* |
Ambion got access to microRNA sequences discovered by Rosetta |
Ambion will adapt its microRNA platforms to detect, quantify and functionally characterize the sequences for use in developing products for research (9/12) |
Sareum |
Infinity Pharmaceuticals Inc.* |
Sareum will provide protein structure determination services for Infinity |
Sareum will attempt to show how Infinity's drug candidates interact with target receptor proteins; terms were not disclosed (9/22) |
SD |
Adventrx Pharmaceuticals Inc.(AMEX:ANX) |
Adventrx got U.S. rights to ANX-530, an emulsion formulation of vinorelbine tartrate |
Vinorelbine is used in cancer treatments; Adventrx's license includes all rights to future vinca alkaloid formulations (10/4) |
SIRS-Lab |
Biosite Inc. (BSTE) |
Collaboration to evaluate and potentially commercialize sepsis markers |
Biosite will make antibodies to targets provided by SIRS-Lab; terms of the deal were not disclosed (8/25) |
Sontra Medical |
EpiVax Inc.* |
Collaboration to investigate the topical delivery of EpiVax's therapeutic HIV vaccine and other DNA vaccines |
They will use Sontra's SonoPrep ultrasonic skin permeation device in the effort; terms of the deal were not disclosed (10/20) |
Stem Cell |
Serologicals Corp. (SERO) |
Deal to manufacture and market embryonic stem cell media for the research market |
Serologicals subsidiary Chemicon International Inc. got worldwide rights to make and market a fully formulated cell culture media (10/6) |
Stem Cell |
Deltagen Inc. (PK:DGENQ) |
Deltagen licensed rights to Stem Cell's IRES technology to make and sell knockout mice |
Stem Cell gets $1.2M up front, royalties on resulting sales and will be provided genetically engineered mice (9/5) |
U.S. Biodefense |
AntiCancer Inc.* |
Collaboration to develop approaches for using human neural crest stem cells and their potential in transplantation |
The goal is to develop treatments in the area of central nervous system diseases; terms of the deal were not disclosed (10/18) |
VasGene |
MedImmune Inc. (MEDI) |
Deal to develop cancer- focused monoclonal antibodies targeting the EphB4 subfamily of receptor tyrosine kinases, as well as its ligand, EphrinB2 |
VasGene will provide R&D support and is entitled to an up-front fee along with milestone and royalty payments; Med- Immune will develop and commercialize any resulting products (9/8) |
VisiGen |
Applied Biosystems Group (NYSE:ABI) |
They entered a definitive agreement to collaborate on sequencing technologies |
Applied Biosystems intends to make an equity investment in VisiGen; terms were not disclosed (10/26) |
VivoQuest |
XTL Bio- pharmaceuticals Ltd.(Israel; XTLB) |
XTL got exclusive rights to VivoQuest technology, including HCV compounds and its compound library |
VivoQuest got an up-front payment of $1.4M in XTL stock; it also is entitled to development and commercialization milestone payments under the asset-purchase deal (9/21) |
Xenogen |
Gene Logic Inc. (GLGC) |
Xenogen will produce and characterize lines of bioluminescent animal models for Gene Logic |
The deal follows an earlier agreement in which Gene Logic purchased Xenogen equipment and licensed biophotonic imaging technology (10/13) |
XOMA Ltd. |
Crucell NV (the Netherlands; CRXL) |
Crucell got expanded rights to XOMA's bacterial cell expression technology |
The deal improved Crucell's position to perform phage display for infectious diseases with third-party collaborators; terms were not disclosed (10/5) |
| | |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets. | |||
To read more on related topics, click on one of the words below.